Lonza to expand

Published: 17-May-2002


Swiss group Lonza's Biotec business sector plans to expand its biophar-maceutical cGMP microbial manu- facturing capacity. To cope with increasing demand for microbial manufacturing services, Lonza is to build a biologics medicines manufacturing plant at a cost of more than SFr100m (€68m). The site will be at Kourim in the Czech Republic, Portsmouth in the US, or Visp in Switzerland. 'The decision to expand our capacity and capabilities in cGMP microbial biopharmaceuticals manufacturing underscores Lonza's commitment to strengthen its leadership position,' said Rene Imwinkelried, head of Lonza Biotec.

You may also like